WALTHAM, Mass., Aug. 17, 2022 (GLOBE NEWSWIRE) — AVAVA Inc. (“AVAVA” or the “Company”), a disruptive medical aesthetics technology platform company providing breakthrough treatments for all skin tones, today announced that its AVAVA pigment disorder product has received FDA 510(k) clearance to treat benign pigmented lesions of the skin, including hyperpigmentation.
Read the full announcement featuring our own Dr. Geronemus at PR Newswire.